PA-BOOMI
16.5.2023 16:01:30 CEST | Business Wire | Press release
BoomiTM, the intelligent connectivity and automation leader, today announced Boomi AI – a first-of-its-kind, simplified user experience that harnesses generative AI to connect and integrate applications, data, processes, people, and things across organizations – creating business outcomes faster than ever before.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005335/en/
Boomi Changes the Integration and Automation Game With Boomi AI (Graphic: Business Wire)
“The introduction of Boomi AI marks yet another milestone in our long history of pioneering innovation in the integration industry,” said Ed Macosky, Chief Product Officer at Boomi. “We pioneered the first low-code, cloud-native integration platform as a service (iPaaS) to disrupt the middleware market 20+ years ago. Then, over a decade ago, Boomi pioneered AI-assisted development with the launch of Boomi Suggest, which further disrupted the market. Now, we are taking our intelligent integration and automation platform to the next level by making it AI-first – enabling AI to responsibly build and complete integrations, and transform automation for our customers.”
In today’s constantly changing market, organizations are making substantial investments to modernize their digital operations. According to IDC, global spending on AI will increase by 26.9% in this next year alone. However, disconnected ecosystems make it difficult for IT teams to focus on strategic initiatives. Fragmented tools, applications, and data can cause confusion and coordination issues, as teams lack a centralized platform for integration, API management, orchestration, and automation, resulting in time spent on maintenance, not innovation.
Boomi’s AI engine is fueled by the company’s approximately 20,000 customers – the largest customer base among integration platform vendors. Boomi AI leverages anonymized metadata, patterns, and best practices from the 200 million integrations made with the Boomi platform to train the AI models to create high-quality integrations across various business processes and applications, such as data management, customer experience optimization, or supply chain processes.
“Boomi’s extensive knowledge base makes our AI engine far more advanced than the AI-assisted development tools available today. It also benefits users by continuously testing patterns to ensure optimal integration design and root out risks and errors early, enabling customers to achieve tremendous gains in efficiency, operational improvements, and other desirable business outcomes,” added Macosky.
With Boomi AI, organizations can:
Design Connections: Boomi AI can design integration processes, application programming interfaces, and master data models with built-in best practices from millions of successful use cases, through a quick command, like, “Connect my CRM and invoice systems.”
Optimize Operations: With Boomi AI’s actionable intelligent insights, users can solve problems proactively, facilitate predictive maintenance, automate updates, and allocate optimal resources to enable software to efficiently self-manage itself. These insights, like “A data attribute in Salesforce has changed. Would you like to apply it across your systems?” make previously menial tasks quick and easy.
Orchestrate Experiences: Boomi AI can interpret intent behind desired business outcomes to orchestrate processes across applications. It enhances decision-making, simplifies tasks, and improves engagement while providing audit history and prompts to confirm intent so that decisions and outcomes are always explainable, creating even greater synergies between IT and the business. With a simple prompt like “Automate invoice processing,” IT teams and business leaders can focus on what matters most.
Enable Responsible AI Development: Boomi’s AI algorithms are trained to avoid biases and unfairness with established ethical guidelines for the development and use of AI within the Boomi platform. These guidelines confirm that Boomi’s AI technology is used in a transparent and accountable manner, and that it does not violate any ethical principles or laws. Additionally, Boomi has achieved U.S. Federal Risk and Authorization Management Program (FedRAMP) Authorization Moderate, a government-wide program that provides a standardized approach to security assessment. Boomi AI does not store any customer-specific information of any kind.
“In today's fast-paced market, organizations need more powerful tools that enable them to outperform, and AI presents a potent new avenue to do this,” says Dion Hinchcliffe, VP and Principal Analyst of Constellation Research. “By embracing an important new AI-first approach, organizations can unlock new levels of efficiency, innovation, and competitive advantage, to immediately capture opportunity as well as ensure their business remains future-ready.”
As the pioneer of cloud-native integration platform as a service (iPaaS), Boomi celebrates a growing community of more than 100,000 members, and one of the largest arrays of global systems integrators (GSIs) in the iPaaS space. The company boasts a worldwide network of partners, including Accenture, Deloitte, SAP, and Snowflake; and works with the largest hyperscaler cloud service providers, including Amazon Web Services, Google, and Microsoft, among others.
Included on the Deloitte Technology Fast 500™ and Inc. 5000 lists as one of America’s fastest growing and most innovative technology companies, Boomi was recently named to Nucleus Research's list of “Hot Companies to Watch in 2023.” The company has also won numerous awards, including three International Stevie® Awards, for Company of the Year (two years in a row) and Product Innovation; the Gold Globee® Award in the Platform as a Service (PaaS) category; the Merit Award for Technology in the Cloud Services category; the Stratus Award as a Global Leader in Cloud Computing 2022; and received the prestigious 5-star rating in the CRN Partner Program Guide for two consecutive years.
Join the Boomi AI waitlist at boomi.ai.
Additional Resources
- Read more about accelerating outcomes with Boomi AI
- Learn more about the Boomi platform
- Explore the Boomiverse Community
- Follow Boomi on Twitter, LinkedIn, Facebook, and YouTube
About Boomi
Boomi aims to make the world a better place by connecting everyone to everything, anywhere. The pioneer of cloud-based integration platform as a service (iPaaS), and now a category-leading, global software as a service (SaaS) company, Boomi touts the largest customer base among integration platform vendors and a worldwide network of approximately 800 partners – including Accenture, Capgemini, Deloitte, SAP, and Snowflake. Global organizations turn to Boomi’s award-winning platform to discover, manage, and orchestrate data, while connecting applications, processes, and people for better, faster outcomes. For more information, visit http://www.boomi.com.
© 2023 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005335/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 15:00:00 CEST | Press release
Joint Development Talks with Global Optical Communications companiesExpanding Partnerships to Provide Total Transceiver Solution1,800 Patents Secured for High-Performance Optical Communications Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is streng
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
